Stemcell Technologies Stemcell Technologies 25 Years

Webinar: Maintaining and Assessing High-Quality hPSC Cultures

Register Now
hPSCs hold tremendous promise in a wide range of applications, including regenerative medicine, disease modeling, drug discovery and toxicology. Advancing in popularity alongside CRISPR-Cas9 genome editing, these technologies are being used in combination to generate novel data at a rapid pace. Now that the first clinical trials involving differentiated derivatives of hPSCs are underway, it is only a matter of time before genetically modified hPSC lines are being assessed for their suitability in clinical applications. As a result, there is a renewed focus on cell quality.

In this live webinar, our in-house experts Dr. Andrew Gaffney and Dr. Adam Hirst discuss how you can maintain and assess high-quality hPSC cultures throughout the various stages of your research.

STEMCELL Technologies

Adam Hirst completed his PhD in Stem Cell Biology from the University of Sheffield where his research focused on genomic instability in human pluripotent stem cells. He then worked as a Research Fellow at the University of Nottingham studying the specification of primordial germ cells in non-rodent mammals. Adam is currently a Scientist at STEMCELL Technologies, developing products to facilitate innovative techniques such as gene-editing in human pluripotent stem cells.

Product Manager
STEMCELL Technologies

Andrew Gaffney completed his PhD in Pediatric Oncology from the University of Leeds, UK, where he successfully established a human embryonic stem cell disease model of Ewing sarcoma. He joined STEMCELL Technologies in 2014 as a Global Technical Specialist where he provided advanced customer support in the areas of human pluripotent stem cell (hPSC) maintenance and differentiation. Since 2016, Andrew has been working as the Product Manager for STEMCELL's PSC portfolio of products. He works closely with renowned stem cell scientists in both industry and academia to monitor the requirements needed for establishing successful hPSC-based disease models, drug screens and cell therapy applications.

Live Webinar: Maintaining and Assessing High-Quality hPSC Cultures

Tuesday February 27, 2018 - 10am PST | 1pm EST | 6pm UTC

If you are unable to attend the live webinar, please register and we will send you a link to view the recording when it becomes available.

  • Progression of pluripotent stem cells in the clinic
  • hPSC genome editing using RNP-based CRISPR-Cas9
  • Cell quality considerations and implications for future stem cell-based therapies
  • Genomic stability of hPSCs
To learn more about this topic, please visit our collection of online resources on the cell quality attributes of human pluripotent stem cells.